IN8bio is a biotechnology business based in the US. IN8bio shares (INAB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.17 – a decrease of 4.49% over the previous week. IN8bio employs 18 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.17 |
|---|---|
| 52-week range | $0.13 - $1.74 |
| 50-day moving average | $0.21 |
| 200-day moving average | $0.34 |
| Wall St. target price | $3.59 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.57 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.17 from 2025-05-02
| 1 week (2025-04-28) | -4.49% |
|---|---|
| 1 month (2025-04-04) | 12.58% |
| 3 months (2025-02-05) | -40.75% |
| 6 months (2024-11-05) | -53.93% |
| 1 year (2024-05-03) | -83.00% |
|---|---|
| 2 years (2023-05-05) | -92.70% |
| 3 years (2022-05-05) | 2.68 |
| 5 years (2020-05-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -67.7% |
| Return on equity TTM | -154.44% |
| Profit margin | 0% |
| Book value | $0.20 |
| Market Capitalization | $13.8 million |
TTM: trailing 12 months
We're not expecting IN8bio to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, IN8bio's shares have ranged in value from as little as $0.133 up to $1.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IN8bio's is 0.235. This would suggest that IN8bio's shares are less volatile than average (for this exchange).
To put IN8bio's beta into context you can compare it against those of similar companies.
IN8bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Compare pros, cons, research tools and reviews for these two trading platforms.
Some of the best trading apps like Robinhood are SoFi, Tastytrade, Public, eToro, Acorns, Interactive Brokers, E*TRADE and more.
Compare pros, cons, research tools and reviews for these two trading platforms.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.